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Abstract
It has been demonstrated that the development of NKT cells requires CD1d. The contribution of costimulatory molecules in
this process has not been studied. Here we show that in mice with targeted mutations of B7-1/2 and CD28, the TCRb
+a-
Galcer/CD1d
+ (iVa14 NKT) subset is significantly reduced in the thymus, spleen and liver. This is mainly due to decreased
cell proliferation; although increased cell death in the thymi of CD28-deficient mice was also observed. Moreover, in the B7-
1/2- and CD28-deficient mice, we found a decreased percentage of the CD4
2NK1.1
+ subset and a correspondingly increased
portion of the CD4
+NK1.1
2 subset. In addition, the mice with a targeted mutation of either B7 or CD28 had a reduced
susceptibility to Con A induced hepatitis, which is known to be mediated by NKT cells. Our results demonstrate that the
development, maturation and function of NKT cell are modulated by the costimulatory pathway and thus expand the
horizon of costimulation into NKT, which is widely viewed as a bridge between innate and adaptive immunity. As such,
costimulation may modulate all major branches of cell-mediated immunity, including T cells, NK cells and NKT cells.
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Introduction
The notion of costimulation was proposed as the signal 2 for the
activation of T lymphocytes [1–3]. Over the last two decades, B7
and CD28 families have emerged as the prototypical costimulatory
ligands and receptors respectively [4]. Although the main emphasis
inthe fieldhas beenontheroleoftheseinteractionsintheactivation
of T cells, accumulating data have demonstrated that this pathway
also modulates effector function of T cells in cancer rejection [5–7]
and autoimmune diseases [8,9]. Moreover, clear evidence has been
reported that support an important role for costimulation in the
developmentofTcells[10].Thus,the costimulatorypathwaycanin
fact function through the whole life-span of T cells. Another
interesting development in the field is that the costimulatory
molecules ascribed to T cell immunity also modulate innate NK cell
immune responses, including both expansion and effector function
of NK cells [11]. An interesting issue is whether costimulation
modulates the NKT subset, which is generally viewed as the bridge
between innate and adaptive immunity.
NKT cells are a unique subset of T cells expressing both TCR
and NK cell markers [12–16]. However, unlike NK cells, NKT
cells mainly develop in the thymus. In contrast to conventional T
cells, NKT cells respond to antigen presented by the nonpoly-
morphic major histocompatibility complex (MHC) Class I-like
molecule CD1d [14–16]. The TCR of a major subset of NKT cells
is composed almost exclusively of Va14/Ja18 in the mouse and
Va24/Ja18 in human. In mice the TCR receptor a chain is paired
with the Vb8.2, Vb7, or Vb2 TCRb chain. This subset recognize
glycolipids presented by CD1d molecules [15,16]. Almost all NKT
cells are either CD4
+ or CD4
2CD8
2 (DN). Upon stimulation
through their TCR, the NKT cells rapidly produce substantial
amounts of cytokines, such as IL-4 and IFN-c [17,18]. Emerging
data demonstrate that it is involved in immunity against infection
[19] and tumor [20] and in autoimmune disease [21] by either
direct cytotoxicity or secretion of several cytokines.
The developmental relationship between NKT and conventional
T cells has been controversial. Two models have been proposed for
NKT cell development [22,23]. NKT cells might derive from a
distinct precursor that undergoes lineage commitment indepen-
dently of TCR-ligand interactions (pre-committed model). Alter-
natively, they may develop as a byproduct of conventional T cell
development at a certain stage, depending on the ligand they
recognize (TCR-instruction model). Recently, by intrathymic
injection, Gapin et al. showed that NKT cells can be produced in
the thymus from CD4+CD8+ DP thymocyte [24]. An intermediate,
semi-mature CD4
+NK1.1
2 stage has been proposed before NKT
cells finally develop into NK1.1
+ cells that are either CD4
+ or
double negative [25–27]. Moreover, the positive and negative
selection of NKT cells rely on CD1d being presented by
hematopoietic derived DP thymocyte or dendritic cells, respectively
[24,28], but not those presented by thymic epithelial cells. The
details of this selective process are still largely unknown. A largely
unresolved issue is whether the B7-CD28 interaction is involved in
the development of NKT cells. In order to address this question, we
compared the development of NKT cells in WT mice to that in
mice with targeted mutations of B7-1/B7-2 or CD28. Our results
demonstrate that the development and function of NKT cells are
subject to modulation by costimulatory pathways.
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The reduced TCR b
+NK1.1
+ NKT cells in B7-1/2 and CD28
deficient mice
In order to evaluate the role for costimulatory molecules on
NKT development, we compared the percentages of NKT cells in
the central and peripheral lymphoid organs of B7-1/2, CD28
mutant mice with those of NKT cells in the same organs of age
and sex- matched WT mice. In this study, the total NKT cells
were defined as NK1.1
+TCRb
+ cells. As shown in Fig. 1A, TCR
b
+NK1.1
+ cells comprise about 1% of the total thymocytes in WT
mice. After dividing the thymocytes into DN, DP and SP subsets, it
was clear that NKT cells were largely absent from the DP and
CD4
2CD8
+ subsets, as others have reported [15]. About 5% of
DN and 4% of CD4
+CD8
2 thymocytes expressed the NKT
marker in WT mice. A 3–5 fold reduction of the NKT cells was
observed in total thymocytes and DN and CD4 subsets from both
B7-1/2- and CD28- deficient mice. Thus, B7-CD28 interaction is
required for the development of NKT in the thymus.
We also compared the amounts of NKT cells in the spleens and
livers of mice deficient for B7-1/2 and CD28 with those of WT
mice. As shown in Fig. 1B, total TCR b
+NK1.1
+ cells in the spleen
were decreased somewhat as a result of targeted mutation of B7
and CD28. Among the CD4
+ splenocytes, the NKT subset is
reduced by more than 2-fold. However, the reduction in DN NKT
was marginal. The liver is known to be populated with a high
number of NKT cells [29–31]. However, except for the reduction
in NKT among the CD4
+CD8
2 subset in the CD28 deficient
mice, targeted mutation of B7-CD28 did not have a significant
impact on the number of TCR b
+NK1.1
+ NKT cells (Fig. 1C).
Most of the NKT cells recognize glycolipids presented by MHC
class I-like molecule CD1d, and are referred to as iVa14 NKT
cells for being CD1d-restricted NKT bearing the invariant Va14
rearrangement [32,33]. Although the identity of the endogenous
antigen presented by CD1d is still unclear, a synthetic glycolipid
antigen derived from marine sponges called alpha-galactosyl
ceramide (a-GalCer) can be recognized by NKT and potently
stimulate NKT cells via TCR when presented by CD1d [34].
Recently, the development of aGalCer/CD-1d tetramer, which
recognizes invariant Va14–Ja281 TCR, provides another power-
ful tool to identify iVa14 NKT cells. aGalCer/CD-1d tetramer
positive cells comprised about 80% of NK1.1
+TCRb
+ cells
[35,36]. Those aGalCer/CD-1d tetramer negative cells were
identified as different subsets of NKT cells, which are preferen-
tially localized in spleen and bone marrow and are predominantly
of the CD8
+ (or DN) phenotype [23]. In this study, we used the
tetramer to further characterize the TCR b
+NK1.1
+ cells in B7-1/
2 and CD28 deficient mice. As shown in Fig. 2, about 90% of the
TCR b
+NK1.1
+ cells in WT thymus bind to a-GalCer-CD1d
tetramer. In B7- and CD28- deficient thymus only about 75% of
the TCR b
+NK1.1
+ NKT bind to the tetramer. The reduction of
the a-GalCer-CD1d tetramer binding cells in the spleen and liver
is more severe in the mutant mice. Whereas in WT mice, there
were close to 50% of spleen and liver derived TCR b
+NK1.1
+
NKT cells that bound to the tetramer, and less than 20% of TCR
b
+NK1.1
+ NKT cells in mutant mice showed similar specificity in
the spleen, and the tetramer binding cells were reduced by 2-fold
in the liver of the mutant mice.
B7-CD28 interaction promotes expansion of NK1.1 on the
iVa14 NKT cells
To further characterize the effect of costimulatory molecules on
iVa14 NKT cell development and activation, we analyzed the
number of cells as well as NK1.1, CD44 and CD4 expression
among iVa14 NKT cells. As shown in Fig. 3A, the number of
iVa14 NKT cells was significantly reduced in total lymphocytes
from both the thymus and spleen of B7-1/2 deficient mice. Again,
a qualitatively similar but quantitatively more significant reduction
was detected in CD28 deficient mice. While a small reduction was
observed in the liver of B7- deficient mice, no reduction of iVa14
NKT was observed in the liver of CD28-deficient mice. Thus, the
optimal production of iVa14 NKT cells in the thymus and their
accumulation in the spleens require B7-CD28 interaction.
Recent studies have demonstrated that in normal mice the
NK1.1
+ iVa14 NKT cells are developed from NK1.1
2 iVa14
NKT cells. Interestingly, in B7-1/2 and CD28 deficient mice, the
percentage of NK1.1
+ subsets among iVa14 NKT cells was
significantly reduced, while the NK1.1
2 subsets were significantly
increased by 4-fold in the thymus and 2-fold in the spleen and liver
(Fig. 3B). The iVa14 NKT cells could be further divided into three
major subsets, NK1.1
2CD4
+, NK1.1
+CD4
+ and NK1.1
+CD4
2.
Compared to wild type mice, targeted mutation of both B7 and
CD28 caused a significant reduction in the NK1.1
2CD4
+ subset
and a corresponding increase in the NK1.1
+CD4
2 subset (Fig. 3C).
If the reduction of iVa14 NKT cells from total lymphocytes is
considered, the reduction of the NK1.1
+ iVa14 NKT subset seen
in the mutant mice is even more significant when compared to
WT mice, and the seemingly observed increase in the
NK1.1
2iVa14 NKT subset is actually unchanged (Table 1).
Normal generation of immature iVa14 NKT cells in young
B7- and CD28-deficient mice
In the thymus, a low number of iVa14 NKT cells can be
detected by a-GalCer/CD1d tetramer as early as 5 days after birth
[16,27]. Thereafter, both the percentage and the absolute number
of iVa14 NKT cells increase reaching a peak level at around 6
weeks [24,27]. To determine if B7-CD28 interaction is required
for the generation of iVa14 NKT cells in young mice, we analyzed
the number and phenotypes of iVa14 NKT cells in the thymi and
livers of 8-day old mice. As shown in Fig. 4A, the total percents of
tetramer binding cells in WT and mutant mice were only around
0.03% in the thymus and 0.2% in the liver. Both the number and
the pattern of NK1.1 and CD4 are consistent with that previously
observed in WT mice [27]. Pellicci et al. also demonstrated that at
day11 of fetal thymus organ culture FTOC, a-GalCer/CD1d
tetramer NKT cells only account for less than 5% of total
NK1.1
+TCRb
+ cells [27]. Therefore, the percentage of total NKT
cells at 8 days of age should be more than the above numbers. In
all strains of mice, the majority of iVa14 NKT cells were
immature as they did not yet express NK1.1 (Fig. 4B). Thus, B7-
CD28 interaction appears selectively involved in the maturation of
NKT cells in adult mice.
B7-CD28 interaction promotes proliferation of NKT cells
The reduced cell number can be explained by increased cell
death and/or decreased cell proliferation in the organ. Therefore,
we first tested whether B7 and CD28 deficiencies affect the
survival of iVa14 NKT cells. We compared the number of cells
undergoing programmed cell death in WT, B7-1/2- and CD28-
deficient mice by staining with Annexin V. Since the reduction of
iVa14 NKT cells is limited to the NK1.1
+ subset, we analyzed
apoptosis of TCR
+NK1.1
+ NKT cells. As shown in Fig. 5A, in
WT mice, there were about 3% Annexin V
+ cells in the thymic
TCR
+NK1.1
+ cells and 20% in the same subsets from the spleen.
While the same amount of Annexin V
+ cells was detected in the
thymus of B7-1/2 deficient mice, CD28-deficient mice had an
increase in Annexin V
+ cells in the thymus, but not in the spleen.
Thus, while a contribution of CD28 in the survival of NKT cells in
B7-CD28 in NKT Development
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explain the defect in the development of iVa14 NKT cells.
To investigate whether B7- and CD28-deficiencies affect the
proliferation of NKT cells, we pulsed WT, B7- and CD28-
deficient mice with BrdU and measured DNA synthesis in
TCR
+NK1.1
+ by flow cytometry. As shown in Fig. 5B, about
10% of the TCR
+NK1.1
+ cells were undergoing proliferation in
WT mice during the 4h period, the percentages of BrdU
+ cells
were reduced by 2 fold in B7-1/2 deficient mice and 4 fold in
CD28 deficient mice in the thymus. A significant although less
pronounced reduction was observed in the spleens of the mutant
mice. The more significant inhibition of cell proliferation and
somewhat increased cell death of NKT cells in the thymus might
explain the more severe reduction of NKT cells in mice with
targeted mutations of CD28.
The defective NKT function in costimulatory molecule
deficient mice
Several publications have demonstrated the contribution of liver
NKT cells to a Con A induced murine hepatitis model [37,38]. To
explore if there is possible defective NKT function due to the
reduction of iVa14 NKT cells in B7 and CD28 deficient mice, we
injected Con A into B7-1/2, CD28 deficient mice and WT mice
and measured serum AST and ALT levels for liver damage. The
liver sections were also examined after H&E staining. As shown in
Figure 2. Proportions of iVa14 NKT cells among TCR b
+NK1.1
+ cells isolated from the thymus, spleen and liver of WT, B7-1/2 and
CD28 deficient mice. Total lymphocytes from the thymus (left), spleen (middle) and liver (right) of 8-week old WT (top), B7-1/2- (center) and CD28-
(bottom) deficient mice were stained with TCRb, NK1.1 and a-GalCer/CD1d tetramer. The numbers represent the percentage (Mean6SD, n=9) of a-
GalCer/CD1d
+ cells in the TCR b
+NK1.1
+ population. One representative profile from each group is shown here. The numbers shown on the side of
figures are p value between two indicated groups.
doi:10.1371/journal.pone.0002703.g002
Figure 1. Roles for B7-1/2-CD28 interaction in the accumulation of TCR b
+NK1.1
+ NKT cells in the thymus (A), spleen (B) and liver (C).
B7KO, CD28KO and WT C57BL/6 mice were sacrificed at 8-week of age. Total lymphocytes (left column) from viable cells, CD4
2CD8
2 DN lymphocytes
(middle column) and CD4
+ lymphocytes (right column) were analyzed for the expression of TCRb and NK1.1. One representative profile from each
group is presented. The numbers in the panels are percentages (Mean6SD) of gated NKT cells (n=9). The numbers shown on the side of figures are p
value between two indicated groups.
doi:10.1371/journal.pone.0002703.g001
B7-CD28 in NKT Development
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high serum AST and ALT levels and necrosis of hepatocytes. In
the B7- and CD28- deficient mice, serum AST and ALT levels
were reduced by more than 2-fold in mutant mice as compared
with WT mice (Fig. 6A). Corresponding to this we also observed a
4–5-fold reduction in the necrotic area of the livers from B7- and
CD28- deficient mice (Fig. 6B and C).
Reduced level of Con A induced IFN-c production in B7-
1/2 deficient mice
ConA induced hepatitisisamultiplefactorsdiseaseprocess.Both
Th1 type cytokine IFN-c [39–41] and Th2 type cytokine IL-4
[37,38,42] are crucially involved in the induction of NKT cell-
mediated liver specific inflammation. Moreover, other immunoreg-
ulatory cytokines, such as IL-5 [42,43] and IL-6 [44], had also been
demonstrated to mediate the pathogenesis of this disease. We
investigated whether the reduced susceptibility to Con A induced
hepatitis in B7-1/2 deficient mice is due to defective cytokine
production.Exvivomononuclearcellswereanalyzedat6 hoursafter
Con A treatment in vivo. As shown in Fig. 7A, compared with Non-
treated mice, the percentage of total NKT cells was reduced almost
10-fold in in the livers of ConA treated WT and B7KO mice.
Correspondingly, the conventional T cells, which were identified by
NK1.1
2TCRb
+ cells are relatively increased. Interestingly, those
NKT cells reside in the spleen are not affected. Comparable
numbers of total NKT cells are detected before and after ConA
treatment in the spleens of both strains. This further demonstrated
that NKT cells in the liver play a major role inducing acute
hepatitis. In addition, as shown in Fig. 7B, in WT mice, about 20%
of he liver NKT cells produced IFN-c and 4% of the NKT cells
produced high levelsofIL-4. The amount ofthe same levelofIFN-c
producingcells was reduced by 50% in B7-1/2deficient mice, while
the amount of high levels of IL-4 producing cells was unchanged. It
has been shown that the peak of IL-4 production by NKT cells is
earlier than IFN- c [45,46]. We also confirmed that B7-1/2
deficient NKT cells in the spleen produced less IL-4 compared with
WT mice at an earlier time point (unpublished observation).
However, both IFN-c and IL-4 cytokine secretions in conventional
T cells are barely detectable (Fig. 7C), Therefore, reduced severity
in Con A-induced hepatitis in the B7-deficient mice correlates to
decreased IFN-c by NKT cells.
To further confirm the defect of NKT population in B7 mutant
mice, we adopted an in vitro model to test the reactivity of NKT
cells from WT and B7KO mice to its exogenous ligand, a-
Galactosylceramide (KRN7000). To exclude the effect of weak
costimulatory signaling from B7 mutant antigen presenting cells
[47], both purified CD4 T cells from WT and B7KO mice was
stimulated in vitro with purified CD11c+ dendritic cells from WT
mice. As shown in Fig. 7D, after 48hours co-culture with
KRN7000, CD4 T cells from WT have a stronger response, as
indicated by more IFN-c and IL-4 secretion. Because KRN7000
can only be recognized by iVa14 NKT cell in CD4 population,
this result provided direct evidence of lower number and/or
functional defect of NKT cells in B7KO mice.
Discussion
By comparing WT mice with those with targeted mutations of
CD28 or B7-1/2, we have demonstrated a major contribution of
B7-CD28 interaction in the generation of iVa14 NKT cells in the
thymus. Two lines of evidence presented here suggest that B7-
CD28 interaction is required for the expansion of more mature
NK1.1
+ iVa14 NKT subsets. First, the number of iVa14 NKT
cells in young mice, which are predominantly NK1.1
2,i s
unaffected by these mutations. Second, the overall number of
NK1.1
2 iVa14 NKT cell was largely unaffected in the mutant
adult mice, while the NK1.1
+ iVa14 NKT cells were drastically
reduced. Since earlier studies demonstrated that NK1.1
2 iVa14
NKT cells are the precursors of NK1.1
+ iVa14 NKT [26,27], our
data indicated that B7-1/2-CD28 interaction is not required for
the generation of NKT cell precursors. The co-stimulation-
dependent expansion of mature NKT is largely due to a critical
contribution of B7-CD28 interaction in proliferation of the NKT
cells as the incorporation of BrdU into the NK1.1
+ NKT cells was
drastically reduced. However, the percentage of apoptotic cells
was unchanged in the B7-1/2-deficient mice and only marginally
increased in the CD28-deficient mice.
As a consequence of defective NKT maturation in the thymus,
we observed a significant reduction of the mature NKT cells in the
spleen and liver, the major residences of the NKT cells.
Nevertheless, the defects in the periphery were somewhat less
pronounced than what was observed in the thymus. Theoretically,
this can be due to increased emigration from the thymus,
increased survival and increased proliferation in the mutant mice.
Table 1. Different iVa14 NKT subsets in total lymphocytes of
thymus, spleen and liver in WT, B7-1/2 and CD28 deficient
mice.
WT B7KO CD28KO
Thymus NK1.1
2CD4
+ 0.0560.02 0.0660.01 0.0660.01
NK1.1
+CD4
+ 0.5260.23 0.1360.02* 0.0360.01*
NK1.1
+CD4
2 0.360.15 0.0360.01* 0.0360.01*
Spleen NK1.1
2CD4
+ 0.2160.04 0.2260.05 0.1660.03
NK1.1
+CD4
+ 0.5360.07 0.2360.06** 0.1360.05***
NK1.1
+CD4
2 0.160.01 0.0360.01*** 0.0260.01***
Liver NK1.1
2CD4
+ 0.4860.26 1.2160.29* 0.6860.21
NK1.1
+CD4
+ 1.3460.44 1.4660.33 0.6460.19*
NK1.1
+CD4
2 0.7260.26 0.360.05* 0.2160.05*
Lymphocytes from thymus, spleen and liver of age and sex-matched WT, B7-
1(-/-)/B7-2(-/-) or CD28(-/-) mice were analyzed by flow cytometry. The iVa14
NKT cells were identified based on expressing TCRb and binding to the a-
Galcer/CD1d tetramer. Data shown are means and SD of the percentage of
given subsets in total viable lymphocytes (n=4). Similar data were obtained in
another experiment involving 5 mice per group.
*P,0.05,
**P,0.01,
***P,0.001.
doi:10.1371/journal.pone.0002703.t001
Figure 3. Quantitative and phenotypic variation of iVa14 NKT cells in the thymus, spleen and liver of WT, B7-1/2 and CD28 deficient
mice. Total lymphocytes from the thymus (left), spleen (middle) and liver (right) of 8-week old WT (top), B7-1/2 (center) and CD28 (bottom) deficient
mice were analyzed. A. The quantification of iVa14 NKT cells. The numbers represent the percentage (Mean6SD, n=9) of iVa14 NKT cells. B. The
expression of CD44 and NK1.1 among the gated iVa14 NKT cells. The numbers represent the percentage (Mean6SD) of NK1.1
2 iVa14 NKT cells. C.
The expression of CD4 and NK1.1 from gated iVa14 NKT cells. The numbers represent the percentage (Mean6SD) of NK1.1
2CD4
+ (upper left) and
NK1.1
+CD4
2 (lower right) iVa14 NKT cells. One representative profile from each group is shown here. The numbers shown on the side of figures are p
value between two indicated groups.
doi:10.1371/journal.pone.0002703.g003
B7-CD28 in NKT Development
PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2703Figure 4. B7- and CD28-deficiency does not affect the generation of immature iVa14 NKT cells in young mice. Total lymphocytes from
the thymus (upper panel) and liver (lower panel) of 8-day old WT (left), B7-1/2- (middle) and CD28- (right) deficient mice were analyzed. The numbers
represent the percentage (Mean6SD, n=4) of iVa14 NKT cells (A) and the percentage (Mean6SD, n=4) of individual subsets from gated iVa14 NKT
cells (B). One representative profile from each group is shown.
doi:10.1371/journal.pone.0002703.g004
B7-CD28 in NKT Development
PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2703We have not observed increased proliferation of NKT in the
periphery of the mutant mice. In fact, we have observed decreased
proliferation of NKT in the mutant mice. However, we have
observed a decreased apoptosis of NKT cells in the spleens of B7-
deficient mice. A similar trend was also observed in the CD28-
deficient mice. The increased survival explains the lack of 1:1
Figure 5. B7-CD28 interaction promotes proliferation but not survival of NKT cells. 5–7-week old WT, B7KO, CD28KO mice received
intravenous injection of BrdU. The lymphocytes from the thymus (top) and spleen (bottom) were harvested 4 hours later and stained with antibodies
for TCRb, NK1.1 and BrdU or with Annexin V. A. NKT cells that underwent apoptosis. The numbers represent the percentages (Mean6SD) of apoptotic
cells among TCRb
+NK1.1
+ cells and summarizing data from 2 independent experiments involving a total of 6 mice in the WT and CD28 mutant group,
and 3 in B7-1/2 mutant mice. B. NKT cells undergo proliferation in vivo as revealed by incorporation of BrdU. The numbers in the panels indicate
means and SD (n=3) of the percentages of NKT cells that have incorporated BrdU in the thymus. FITC conjugated mouse IgG1, k was used as isotype
control (right). One representative profile from each group is shown.
doi:10.1371/journal.pone.0002703.g005
B7-CD28 in NKT Development
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spleen and liver. Another unexplained observation is the more
severe phenotype observed in CD28-deficient mice as compared
to B7-deficient mice. Since B7-1/2 interacts with both CD28 and
CTLA-4, it is theoretically possible to explain the discrepancies
between B7-1/2-deficient mice and CD28-deficient mice by
invoking an opposite function of these two receptors. The fact
that the deficiency was observed in older mice and that the CTLA-
4-deficient mice do not survive to adulthood have made it difficult
to test this hypothesis.
Concanavalin A–induced (ConA-induced) hepatitis in mice is a
well-characterized model of T cell–mediated inflammatory liver
disease. Recently, it has been demonstrated that invariant NKT
(iNKT) cells play a key role in the development of ConA-induced
hepatitis. Both Ja18
2/2 and CD1d
2/2 mice that lack iNKT cells
are resistant to ConA-induced hepatic injury [37,38,48]. In
addition, the adoptive transfer of hepatic mononuclear cells from
wild-type mice, but not from CD1-deficient mice, sensitized gld
mice to Con A-induced hepatitis [37]. The later results
demonstrated that NKT cell, other than other cell, is the major
mediator of the disease process. Here we demonstrated that the
B7-1/2- and CD28-deficient mice are more resist to the disease. In
this model, IL-4 secreted by mainly NK1.1
2 iVa14 NKT cells,
was demonstrated to play a crucial role in causing NKT cells to
express FasL and to contribute to Fas/FasL-mediated liver injury
in an autocrine fashion [37,38,42]. Although our presented data
appear to refute a role for IL-4 production by NKT cells, this is
likely due to the fact that the data presented was obtained at
6 hours when the peak of IL-4 production had weaned [45,46]. In
addition, IFN-c produced by NK1.1
+ iVa14 NKT cells is also very
important in mediating the disease process. IFN-c can activate
resident Kupffer cells and recruit macrophages to produce TNF-a,
which subsequently causes liver injury [37], induces proliferation
and cytotoxicity of NK cells [40] and regulates IL-4 signaling as
well as its own signaling through induced suppressor of cytokine
signaling (SOCS-1) [41]. Thus, the significant reduction of
NK1.1
+ iVa14 NKT cells may alleviate Con A-induced hepatitis
in B7- and CD28- deficient mice by abrogating the production of
IFN-c. This hypothesis is supported by our analysis of ex vivo
NKT cells, which revealed reduced IFN-c producing cells
following in vivo Con A stimulation.
Costimulatory pathways were traditionally viewed as critical
modulators for the induction of T cell responses in peripheral
lymphoid organs [49]. Subsequent studies in tumor [5–7] and
autoimmune disease [8] models have revealed a critical contribu-
tion to the effector phase of T-cell immunity. More recent studies
expand its contribution to differentiation of immature thymocytes
and negative selection of T cells [10,50]. In addition, the function
of costimulatory molecules may extend beyond adaptive immu-
nity, as several groups have suggested a role for the activation of
NK cells [11]. Our data presented here demonstrate a role for T
cell costimulation in both the development and function of NKT
cells, which is widely regarded as a bridge between adaptive and
innate immunity. Taken together, it is possible that costimulatory
molecules modulate all major branches of cell-mediated immunity,
including T cells, NK cells and NKT cells.
Materials and Methods
Experimental animals
Wild-type C57BL/6j, B7-1/2 double knockout and CD28
knockout mice on C57BL/6j background were purchased from
Figure 6. Con A induced hepatitis is alleviated in B7- and CD28- deficient mice. Eight-week old B7KO, CD28KO and C57BL/6 mice received
intravenous injection of Con A at a dose of 20 mg/kg. Sixteen hours later, serum and liver tissues from individual mice were harvested. A. Serum ALT
and AST levels. B. One representative section from each group showing the pattern of liver injury. C. Average percentages of area with injuries from
3–4 sections per mouse and 4–5 mice per group.
doi:10.1371/journal.pone.0002703.g006
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of Mice were maintained in the University Laboratory Animal
Research Facility at The Ohio State University and The
University of Michigan under specific-pathogen-free conditions.
All animal experimental procedures were reviewed and approved
by The Ohio State University and University of Michigan
Institutional Animal Care and Use Committees.
Cell Preparation
Single cell suspensions from the thymus and spleen were
prepared by mechanical disruption in cold, serum free RPMI 1640
medium. The liver was perfused with 1xPBS via portal vein. Then,
the liver fragments were incubated with 1mg/ml Collagenase type
IV (Sigma, C5138) in 10mM Hepes-NaOH buffer (150 mM
NaCl, 5 mM KCl, 1 mM MgCl2 and 1.8 mM CaCl2, pH 7.4) for
1 h at 37uC and gently dissociated. The whole material was passed
through a syringe several times to get a single cell suspension. The
liver mononuclear cells were recovered from the interface of 40%
and 60% percoll after centrifugation. Red blood cells from single
cell suspensions were removed by brief hypotonic lysis before cell
surface staining.
Antibodies and flow cytometry
Both cell surface markers and intracellular staining were
analyzed by flow cytometry (Becton Dickinson, Mountain View,
CA). The fluorescein-conjugated antibodies anti-CD4 (GK1.5),
anti-CD8 (53-6.7), anti-TCR b chain (H57-597), anti-CD44
(IM7), anti-CD25 (PC61) and anti-NK1.1 (PK136) were pur-
chased from BD PharMingen (San Diego, CA, USA). Phycoer-
ythorin-conjugated a-GalCer loaded CD1d tetramer was pre-
pared as described [28,36]. The fixation and permeabilization
solution kit (Cytofix/Cytoperm
TM, BD Pharmingen) was used for
intracellular staining according to the manufacturer’s protocol.
The samples were analyzed by flow cytometry. Data acquisition
was performed on a FACSCalibur instrument with CELLQUEST
software (Biosciences, Mountain View, CA), and data were
analyzed using FLOWJO software (Tree Star, Inc., Ashland, OR).
Cell death and proliferation assay
The apoptotic lymphocytes were determined by their binding to
Annexin V. After cell-surface staining, the cells were resuspended
in Annexin V (BD PharMingen), dissolved in 10 mM Hepes,
140mM NaCl, 2.5mM CaCl2 and stained at room temperature for
15 minutes and then analyzed within an hour. To measure the
proliferation of lymphocytes in vivo, mice were injected intraper-
itoneally (i.p.) with BrdU (1 mg/mouse in 100 ml PBS). Four hours
later, the mice were sacrificed and single lymphocytes were
Figure 7. The reduction of IFN-c production among TCR
b
+NK1.1
+ cells isolated from the liver of B7-1/2 deficient mice.
Eight-week old WT (top) and B7-1/2- (bottom) deficient mice received
intravenous injection of Con A (25mg/kg). The mice were sacrificed six
hours later. After perfusion the total number of mononuclear cells from
the liver and spleen were stained with TCRb, NK1.1, anti-mouse IFN-c or
IL-4 mAbs, or fluorescence conjugated isotype control. A. The
percentage of total NKT cells (NK1.1
+TCR b
+) and conventional T cells
(NK1.1
+TCR b
+) in the spleen and liver from Non-treated (left) and ConA
treated mice (right). B. The percentage of cytokine producing cells
among the NK1.1
+TCR b
+ population. C. The percentage of cytokine
producing cells among the NK1.1
2TCR b
+ population. The numbers
represent the percentage (Mean6SD) of one representative profile from
each group is shown. The experiment was repeated twice; 7–8 mice
were included in each group. D. Cytokine secretion of purified CD4 T
cells from WT and B7KO mice stimulated by KRN7000. The numbers
represent the profile of purified CD4 T cells from 3 mice in each group.
The experiment was repeated twice.
doi:10.1371/journal.pone.0002703.g007
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with a BrdU Flow Kit, as described by manufacturer (BD
PharMingen).
Induction of ConA induced hepatitis
Con A (Sigma, C0412) was dissolved in pyrogen-free PBS and
i.v. injected into mice through the tail vein at a dose of 20mg/kg.
Sera from individual mice were obtained 16 h after Con A
injection. Alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) activities were measured by the standard
photometric method using Hitachi type 911 automatic analyzer
(Tokyo). 25mg/kg Con A was used for short-term stimulation, and
the splenocytes and hepatocytes were harvested 6 hours later for
intracellular cytokine staining.
Histological Examination
The livers from Con A treated mice were harvested after 16 h
and then fixed in 10% formalin, embedded in paraffin, sectioned
and stained with hematoxylin and eosin for histological examina-
tion. Specimens were examined under a light microscope. 3–4
images were collected from each section and the injured area was
measured with MCID Analysis 7.0 (Imaging Research Inc.,
Ontario, Canada).
In vitro stimulation of purified CD4 cells with a-
Galactosylceramide
Spleens were harvested from 10–12 weeks old WT C57BL/6
and B7-1/2 mutant mice. Single cell suspension were treated for
45 min with 400 U ml
21 collagenase type IV and 50 mgm l
21
DNase I (Boehringer, Mannheim, Germany) before were
incubated with anti-CD11c-coated magnetic beads. CD11c
+ cells
were positively selected according to the manufacturer’s procedure
(Miltenyi Biotec, Bergisch-Gladbach, Germany). Then all the
flow-through was depleted with antibody mixture containing rat
monoclonal antibodies against mouse CD45R (B220), CD11b
(Mac1), CD16/32(2.4G2), CD11c (HB224) and CD8 (TIB210)
according to manufacturer’s manual (DYNAL, Oslo, Norway).
Cell suspensions contained about 90% of CD11c
+ cells and CD4
+
cells respectively. After purification, 7610
5 CD4 cells from either
WT C57BL/6 or B7-1/2 mutant mice were co-cultured with
36105 CD11c
+ cells in 1ml Bruff’s medium containing different
concentration of a-Galactosylceramide (KRN7000). 48 hours
later, the supernatant was harvest for the detection of secreted
INF-c and IL-4 with ELISA. The relative amounts of cytokines
were shown by absorbance read at 490nm (OD490nm).
Statistical Analysis
Data were statistically analyzed with two-tailed student T-test.
P,0.05 is significant and p,0.01 is highly significant.
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